Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VRNA | US
3.30
11.49%
Healthcare
Biotechnology
30/06/2024
04/10/2024
32.01
30.81
32.88
30.76
Verona Pharma plc a clinical stage biopharmaceutical company focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease asthma and cystic fibrosis. It is developing ensifentrine in three formulations including nebulizer dry powder inhaler and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London the United Kingdom.
View LessPositive Momentum
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
Midcap (2B - 10B USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
69.8%1 month
56.9%3 months
69.4%6 months
64.3%-
-
13.88
1.30
0.50
-20.89
2.53K
-
-127.97M
2.60B
2.60B
-
-
-
-
-56.85
7.11
11.38
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
5.34
Range1M
8.38
Range3M
17.32
Rel. volume
1.25
Price X volume
37.55M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kymera Therapeutics Inc | KYMR | Biotechnology | 43.06 | 2.83B | -4.31% | n/a | 12.87% |
PTC Therapeutics Inc | PTCT | Biotechnology | 35.1 | 2.70B | -3.65% | n/a | -40.35% |
Edgewise Therapeutics Inc. | EWTX | Biotechnology | 28.4 | 2.66B | 4.18% | n/a | 0.98% |
Zai Lab Limited | ZLAB | Biotechnology | 26.36 | 2.63B | 2.93% | n/a | 11.88% |
Protagonist Therapeutics Inc | PTGX | Biotechnology | 44.37 | 2.61B | -1.36% | 16.38 | 2.03% |
Geron Corporation | GERN | Biotechnology | 4.32 | 2.60B | -2.70% | n/a | 28.38% |
IDEAYA Biosciences Inc | IDYA | Biotechnology | 29.97 | 2.53B | -5.46% | n/a | 0.20% |
Veracyte Inc | VCYT | Biotechnology | 32.84 | 2.52B | -2.83% | n/a | 1.83% |
ACADIA Pharmaceuticals Inc | ACAD | Biotechnology | 15.1 | 2.50B | -0.20% | 82.58 | 11.16% |
Agios Pharmaceuticals Inc | AGIO | Biotechnology | 41.325 | 2.48B | -1.11% | n/a | 9.78% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -20.89 | 0.76 | Cheaper |
Ent. to Revenue | 2,531.50 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 13.88 | 14.10 | Par |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 69.44 | 74.67 | Par |
Debt to Equity | 1.30 | -1.82 | Expensive |
Debt to Assets | 0.50 | 0.26 | Expensive |
Market Cap | 2.60B | 3.73B | Emerging |